Trial Profile
A Phase I/II Study of IMCnyeso, HLA- A 0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A 0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs IMCnyeso (Primary)
- Indications Carcinoma; Malignant melanoma; Non-small cell lung cancer; Synovial sarcoma; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms ImmTAC
- Sponsors Immunocore
- 02 Jul 2021 Status changed from active, no longer recruiting to discontinued.
- 12 Apr 2021 Planned End Date changed from 1 Apr 2021 to 1 May 2021.
- 12 Apr 2021 Planned primary completion date changed from 1 Mar 2021 to 1 May 2021.